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AIMS: To describe past trends and future projections for the number of intravitreal injections being administered at a large tertiary
hospital in London, United Kingdom.
METHODS: Retrospective data from Moorfields Eye Hospital were collected using the electronic medical record system. Descriptive
statistics were used to visualise overall trends. Time series forecasting was used to predict the number of injections that will be
administered up to and including the year 2029.
RESULTS: The number of injections has increased nearly 11-fold from 2009 to 2019, with a total of 44,924 injections delivered in
2019. The majority of injections were given for the treatment of neovascular age-related macular degeneration. Aflibercept formed
87% of injections administered in 2019. The number of injections is predicted to continue to increase every year, with nearly 83,000
injections forecasted in the year 2029.
CONCLUSION: The demand for intravitreal injections has increased substantially over the last decade and is predicted to further
increase. Healthcare systems will need to adapt to accommodate the high demand. Other solutions may include longer-acting
therapies to reduce the treatment burden.
Eye; https://doi.org/10.1038/s41433-021-01646-3
INTRODUCTION
The availability of intravitreal therapy for the treatment of retinal
disease has expanded substantially over the last decade and is the
first-line treatment for neovascular macular disease [1] and foveal-
involving macular oedema. Anti-vascular endothelial growth
factor (anti-VEGF) drugs form the majority of intravitreal ther-
apeutics and are administered as frequently as every four weeks,
often for many years.
Several anti-VEGF drugs have undergone regulatory approvals.
Pegaptanib was the first anti-VEGF drug to be licensed by the
Food and Drug Association (FDA) for the treatment of neovascular
AMD in the USA in 2004. It was subsequently approved by
the European Medicines Agency (EMA) in 2006 [2]. However,
pegaptanib was not recommended as a treatment for neovascular
AMD by the National Institute for Health and Care Excellence
(NICE) [3]. Ranibizumab (Lucentis, Genentech, San Francisco,
California, USA/Novartis Pharmaceuticals, Basel, Switzerland),
shown to be more effective than pegaptanib, was the second
anti-VEGF drug to be licensed by the FDA for the treatment of
neovascular AMD in the USA in 2006 [4], by the EMA in 2007 [2],
and became the first anti-VEGF drug to obtain NICE approval in
August 2008 [3]. Aflibercept (Eylea, Regeneron, Tarrytown, New
York, USA, and Bayer, Berlin, Germany) was subsequently the third
anti-VEGF drug to receive licensing by the FDA in 2011 [5], and by
the EMA in 2012 [6], and was approved by NICE in July 2013 [7].
Bevacizumab (Avastin, Genentech/Roche), also an anti-VEGF drug,
has shown to be as efficacious as ranibizumab [8, 9] but has not
been licensed for intravitreal use. It is however often used in many
other parts of the world due to its significantly lower cost price or
is used for indications falling outside of current licensing
regulations. In China, the anti-VEGF drug conbercept was
approved for neovascular AMD in 2013 after promising preclinical
studies, with phase III studies still in progress. Anti-VEGF drugs
were first approved for neovascular AMD, but have since been
widely approved for several other common conditions such as
choroidal neovascularisation secondary to myopia, and macular
oedema secondary to diabetes or vein occlusion. Other available
intravitreal therapeutics include steroids, anti-virals, recombinant
protease enzymes, and anti-tumour necrosis factor drugs.
At Moorfields Eye Hospital (MEH), a large tertiary referral centre
in the United Kingdom, the Retinal Therapy Unit (RTU) was
established in 2008 as an outpatient clinic to deliver these
injections. In February 2016, Moorfields introduced a larger RTU to
accommodate the increasing number of patients that would
benefit from treatment. The demand for treatment is still growing
and is associated with several factors. Most treated conditions,
particularly neovascular AMD, are highly age-dependent. With an
ageing population, the number of individuals at risk of these
conditions and requiring treatment is increasing substantially.
In addition, as new drugs continue to be developed, and receive
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approval for a growing number of conditions, the trajectory of the
number of patients requiring treatment is expected to increase
even further, particularly if drugs are approved for more common
conditions such as dry AMD. Furthermore, within each condition,
there is an increasing spectrum of indications. For example,
neovascular AMD is being treated at an earlier stage in patients
with better visual acuity than in the past, and recent trials have
shown proliferative diabetic retinopathy may be successfully
delayed with intravitreal therapy [10]. Thus, it is crucial to predict
the demand for these therapies to ensure healthcare systems
can accommodate patients who require sight-saving treatment
without delay.
We report the number of intravitreal injections being delivered
at MEH, including one large centre (City Road) and several smaller
satellite sites. We forecast the number of injections that will be
delivered over the next 10 years given the current trend. We also




Weekly and monthly injection data were extracted from the MEH
electronic medical record system in an anonymised format. Data were
aggregated from one large teaching hospital (City Road), and several
smaller eye units operated by Moorfields (Croydon University Hospital,
Darent Valley Hospital, Ealing Hospital, Loxford Polyclinic, Northwick Park
Hospital, Potters Bar Community Hospital, St. Ann’s Hospital, St. George’s
Hospital, Sir Ludwig Guttmann Health and Wellbeing Centre). All sites
follow the same treatment protocols. Data included the number of patients
receiving unilateral or bilateral injections, the conditions being treated, and
the number of drugs being administered, per week and month at each site.
Conditions were grouped by age-related macular degeneration (AMD),
diabetic macular oedema (DMO), retinal vein occlusion (RVO), myopia, and
others (or unknown). The other category also contains patients that were
given treatment for AMD, DMO, or RVO but were not within the NICE
criteria for treatment [1, 11–15]. Injection drugs included ranibizumab,
bevacizumab, aflibercept, and others (intravitreal steroid [e.g. triamcino-
lone], intravitreal steroid implant [e.g. dexamethasone, fluocinolone
acetonide], ocriplasmin, foscarnet, adalimumab).
This study was conducted in accordance with the Declaration of Helsinki
and the UK’s Data Protection Act. Permission for data collection and
analysis was provided through registration as a clinical audit (CA17/MR/28).
The only retrospective anonymised data were used without the active
involvement of patients.
Statistical analysis
Descriptive statistics were used to summarise the data. The dataset was
stratified by drug and condition. For the latter, we analysed how many
visits comprised bilateral injections. Data analysis was performed in Python
3.6. Forecasting analysis was performed to predict the number of monthly
injections that will be delivered up to the end of the year 2029. This was
carried out using the open-source Prophet package [16, 17], an additive
regression model, which uses historical injection data to fit future trends.
For this model, historical monthly data between 2008 and 2019 was input
to the model. The output was a forecast of the number of injections per
month between January 2020 and December 2029, inclusive, with 95%
confidence intervals. The model automatically removes outliers and
considers seasonality effects, for example, the model accounts for the
reduced service that operates every December due to the holiday season.
For the purpose of this analysis, only the number of injections delivered
per month were fed into the model, and excluded other data such as
patient demographics.
RESULTS
Total number of injections
The first recorded injection was given in August 2008, with only a
total of 361 injections given in that year. Between August 2008
and December 2019 inclusive, 18,100 patients and 22,211 unique
eyes received a total of 252,263 injections. In 2009, the first full
year of operation, 4143 injections were delivered to 1375 patients
(1513 eyes, 8717 patient attendances). The total number of
injections increased almost 11-fold to 44,924 injections (8617
patients, 10,258 eyes, 46,520 patient attendances) in 2019.
Figure 1 shows the number of patient attendances and the
number of injections delivered per week. The greatest number of
injections administered in a single week was 1071 in the second
week of December 2019––one of the last few data points
collected. Between 2008 and 2012, while ranibizumab was the
only NICE-approved drug for the treatment of neovascular AMD
[3] and was provided on a pro re nata treatment regime, the
average ratio of patients to injections was 1.95:1. Aflibercept was
introduced in 2013 [7], licensed for up to 12-weekly doses, and
commonly provided using fixed dosing in the first year of
treatment followed by a treat and extend regimen [18].
Consequently, patients were switched onto this drug and the
ratio of patients to injections reduced to 1.14:1, indicating that the
majority of patients received treatment at every visit. Figure 1
clearly shows the shift between 2013 and 2014 from pro re nata
treatment, with a low ratio of injections to patient attendances, to
treat and extend with a high ratio of injections to patient
attendances. The number of injections given per week per site is
shown in Supplementary Figures 1 and 2.
The monthly number of patients entering the RTU and exiting
(i.e. last appointment in the RTU) is shown in Supplementary
Figure 3. The ratio is also presented (number exiting divided by
the number entering). A ratio of <1 means that more patients are
entering than exiting. While the ratio has been increasing over
time, it remained <1 until August 2019, meaning more patients
had their last appointments in the RTU in the last third of 2019.
Conditions receiving therapy
Neovascular AMD was by far the most commonly treated
condition, accounting for 67.4% of all injections in 2019, and as
high as 87.7% in 2012 (Fig. 2a). The number of injections provided
for neovascular AMD has increased every year, but with a
declining growth factor. Between 2012 and 2013, a relative
increase of 30.1% was observed, whereas only a relative change of
+5.0% was seen between 2018 and 2019. In 2019, 26,048
injections were delivered for neovascular AMD.
Anti-VEGF drugs were approved for use in DMO and RVO in
early 2013 [11, 13], and their use in these conditions has risen
steadily. The proportion of all injections that were prescribed for
DMO was 17.2% in 2014 and rose slightly to 19.2% in 2019.
Whereas, RVO accounted for 6.8% of injections in 2014, and more
than doubled to 15.9% in 2019. Ranibizumab was approved for
the treatment of myopic choroidal neovascularisation (CNV) in late
2013 [19] and was available on the Moorfields formulary in early
2014. In 2014, only 2.0% of injections were given for this myopic
Fig. 1 Historical trends. Number of patients that attended the
intravitreal injection clinic every week (black), and the number of
injections administered (grey), between August 2008 to December
2019 (inclusive), at Moorfields Eye Hospital. The annotations
highlight when drugs became available on the Moorfields formulary
and for which conditions.















CNV. In 2019, the proportion reduced slightly to 1.7%. The weekly
number of injections given for neovascular AMD, RVO, and DMO
are presented in Fig. 3. The percentage of treated retinal
conditions per site is provided in Supplementary Table 1.
In 2009, 1894 injections were given for ‘other’ conditions.
A significant proportion of this is likely to be attributable to
neovascular AMD, where treatment eligibility was limited and
conditioned on the availability of funding. The number of
injections within this category reduced every year until 2014.
From 2015, the number of injections falling into this category
followed an upward trajectory, with 2324 injections being
performed in 2019, which may be attributable to conditions such
as idiopathic CNV, radiation retinopathy, neovascular glaucoma,
pre-vitrectomy in eyes with proliferative diabetic retinopathy,
and more.
Intravitreal drugs
Ranibizumab accounted for over 95% of all injection drugs from
2008 to 2012 inclusive (Fig. 2b). The use of aflibercept grew rapidly
after it received market authorisation for neovascular AMD [7] and
was available on the Moorfields formulary in 2013. Patients with
neovascular AMD were switched from ranibizumab to aflibercept
in 2013 and 2014. However, ranibizumab was the only drug
licensed for the treatment of macular oedema and myopic CNV
and thus an increase in ranibizumab use was seen in 2015.
A similar switch from ranibizumab to aflibercept was seen for
other conditions as aflibercept was approved for more indications.
Aflibercept was available on the Moorfields formulary for central
RVO in mid-2014, DMO in late-2015, branch RVO in early-2017, and
myopic CNV in mid-2018. In 2019, aflibercept was administered in
87.0% (n= 39,096) of injections, whereas only 8.6% (n= 3866) of
injections were ranibizumab. The use of bevacizumab and other
drugs continues to remain low. The distribution of drugs
administered per site is provided in Supplementary Table 2.
Bilateral injections
Between 2012 and 2019, bilateral injections were performed at an
average of 19.2% visits for those receiving treatment for DMO
(Fig. 4). From 2009 to 2013, bilateral injections were only
performed at 3.0% of visits for patients with neovascular AMD.
This rose sharply between 2014 and 2019, bilateral injections were
given at an average of 10.4% of visits. This proportion appears to
have plateaued for both DMO and AMD despite the increasing
number of injections being given for these conditions. Bilateral
injections were only given to a smaller percentage of patients who
had myopic CNV or RVO. Other conditions that received bilateral
injections included retinal dystrophies and uveitis.
Forecasting the number of injections
The forecasting analysis estimated that, at the current trend, the
number of injections will incrementally rise every year but with a
declining growth factor (Fig. 5, Table 1). At the current rate, the
number of injections that will be delivered in 2029 is ≈82,876 (95%
confidence intervals: 65,540–100,214).
DISCUSSION
In this report, we summarise the trends in the delivery of
intravitreal injections at a large tertiary ophthalmic hospital in
London, United Kingdom. The injection service has grown in
capacity substantially over the last 10 years. Our forecast analysis
predicts that if the current trend continues over the next 10 years,
nearly 83,000 injections will be administered in the year 2029.
The most common indication for intravitreal injections at
Moorfields Eye Hospital is for the treatment of neovascular AMD,
and the second most common indication being DMO, though this
varies by site. For example, at Ealing Hospital, injections are as
commonly indicated for DMO as they are for AMD. This is likely
explained by the variation in the demographics of the populations
at each site such as age, ethnicity, and social determinants of
health, which are known to be risk factors for retinal diseases [20].
Both of these conditions are increasing in prevalence and are
likely to lead to an increasing need for injections. In Europe, the
incidence of late AMD is expected to increase to 700,000 per year
Fig. 2 Number of injections given per year from 2008–2019. a
Stratified by retinal condition, (b) stratified by drug.
Fig. 3 Weekly number of injections per condition. Number of
injections given per week for neovascular age-related macular
degeneration (AMD), macular oedema secondary to retinal vein
occlusion (RVO), and diabetic macular oedema.
Fig. 4 Bilateral treatment. Percentage of patient visits where
injections were given bilaterally, stratified by retinal condition
and year.
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by 2050 due to population growth and lengthening life
expectancy [21]. Similarly, the prevalence of diabetes is increasing
with the changes in lifestyle and diets. In England alone, the total
number of adults with diabetes is projected to rise to 4.6 million in
2030––an increase of 9.5% from 2010 [22]. A significant proportion
of these will benefit from intravitreal therapy. Minassian et al.
estimated that 7.1% of individuals with diabetes in England had
DMO in one or both eyes––of these, 38.9% were estimated to
have clinically significant DMO [23]. Similarly, Keenan et al. found
13.9% of patients managed for diabetic eye disease in the hospital
had clinically significant DMO [24]. Thus, it is essential for hospital
systems to prepare for the increasing demand to ensure injections
can be provided promptly as delay in treatment is known to affect
visual prognosis in AMD and DMO [25, 26]. Longer-acting agents
may be one solution to the predicted demand. Newer anti-VEGF
agents such as brolucizumab may soon be widely available for
patients which may require less frequent therapy [27]. Port-
delivery systems that can be implanted and refilled with anti-
VEGF, and thus aim to reduce treatment burden, are in clinical
trials and have shown positive results [28, 29]. These systems may
allow for up to 6 months between treatments and thus reducing
the frequency of visits to the eye clinic.
The surge in the number of injections being delivered over the
last 10 years is likely multifactorial. Although likely to play a role,
the number of injections cannot solely be explained by an
increasing prevalence of disease as the rate of uptake of injections
has exceeded the prevalence rates. As expected, the number of
injections increased more sharply at junctures where drugs were
approved for DMO and RVO. In addition, the hospital expanded
significantly in February 2016 to cope with and in preparation for
the increasing demand. The creation of this extra capacity and the
ability to treat more retinal conditions led to an increased uptake
of injections at a higher rate than in prior years. Although the
number of injections being administered is still increasing year on
year, the growth factor appears to be declining. This may indicate
that the hospital is reaching its ceiling of available capacity, the
prevalence of disease could be stabilising. While the number of
new patients entering the RTU is still greater than the number
exiting the clinic, the gap between the two is reducing. It has also
been postulated that the age-specific incidence of AMD is
decreasing [30]. Future increases in the growth factor might be
a consequence of the significant increase in disease prevalence or
licensing of drugs for use in further conditions. For example,
clinical trials are currently underway investigating the effective-
ness of intravitreal pegcetoplan [31] and avacincaptad pegol [32]
for geographic atrophy. As geographic atrophy has a higher
prevalence than neovascular AMD, it is likely that a large
population could potentially benefit from these drugs if approved.
Our forecasting analysis was derived using only historical data
without controlling for other variables such as the estimated
future prevalence of disease. With an ageing population in the UK,
the prevalence of age-dependent diseases such as AMD are likely
to increase. In London alone, the population is expected to
increase by 8.5% from 8.9 million individuals in 2019 to 9.66
million in 2029 [33]. Over a third of the London population in 2019
will be over 50 years old––an increase of 500,000 individuals from
2019. While the forecasting did not account for this factor
specifically, the model accounts for historical trends of which
population is one factor. The described future population trend
has also been observed in the last decade and therefore will be
accounted for in historical trends. In addition, in light of the
COVID-19 crisis and the impact of isolation measures, the number
of injections performed at Moorfields in April 2020 fell significantly
[34]. In addition, the last third of 2019 showed that more patients
were exiting the RTU than new patients entering, which may be
explained by the reduction in activity due to the pandemic.
Although the forecast for 2020 will be inaccurate in absolute
numbers, it may still accurately reflect the number of eyes that
would have required treatment. The actual future trajectory will
likely be influenced by multiple factors such as changes in
treatment regimens and protocols, the availability of novel
therapies that may be longer-acting, and the provision to treat
more retinal conditions. In addition, both an increased awareness
of macular disease by the public, and the introduction of optical
coherence tomography into primary eye care [35], may improve
the detection rate of conditions requiring referral and subsequent
treatment into the hospital eye service.
The emergence and upward trajectory in the uptake of
intravitreal therapies for the treatment of multiple retinal condi-
tions illustrate the dramatic speed of adoption, particularly in
conjunction with NICE approvals. In prior analysis of trends of
intravitreal injections in England, Keenan et al. similarly observed a
substantial increase in intravitreal injections for AMD following NICE
approval for ranibizumab [36]. At Oslo University Hospital, Norway,
a similar trend was seen in the uptake of injections from 2006 to
2019, with neovascular AMD forming a similar percentage of
injections [37]. While the mainstay of treatment at this institution is
bevacizumab, there was a significant uptake in aflibercept as a
second-line treatment for neovascular AMD and first-line treatment
for DMO. Our figures clearly illustrate the increase in aflibercept at
Moorfields since it received NICE approval and was available on the
formulary in 2013. As the licensing permits 12-weekly administra-
tion using a treat and extend regimen, the majority of patients
were switched to aflibercept from ranibizumab, with the latter
being recommended on a pro re nata regimen and overall
requiring more frequent visits compared to treat and extend
posology [38]. Visual acuity treatment outcomes have been shown
to be similar between both ranibizumab and aflibercept in
neovascular AMD [39]; however, the need for fewer injections
and clinic visits is beneficial for a system where the demand is high
and growing. Aflibercept is currently licensed for several conditions
including neovascular AMD and macular oedema secondary to
diabetes or vein occlusion. Both anti-VEGF treatments require long-
term administration with many patients remaining within these
clinics indefinitely, particularly for the treatment of neovascular
AMD [40].
In conclusion, these findings show the dramatic speed of
adoption as intravitreal drugs are approved and become available
for additional retinal conditions. The potential introduction of
intravitreal therapy for other more prevalent conditions such as
geographic atrophy would place further significant demand. As
the upward trend is expected to continue, resources will need to
be adequately allocated towards service provision. Here, innova-
tion in new therapies, including longer-acting therapies, and
automation may be necessitated to mitigate the increasing
demand in the assessment and treatment of patients. In addition,
forecasting future trends may aid healthcare systems to plan
resources and secure funding to be able to accommodate the
expected demand.
Fig. 5 Forecasting future trends. Actual number of monthly
injections from 2008 to the end of 2019 (black). Forecasted number
of monthly injections for a 10-year period from 2020 to the end of
2029 with shaded 95% confidence intervals (grey).




What was known before
● Intravitreal drugs are the first-line of treatment for many
retinal diseases. Their use has expanded over the last decade.
What this study adds
● Intravitreal injections were adopted with dramatic speed
over the last decade. As demand is forecasted to increase
further, healthcare systems will need to increase their
capacity, or administer longer-acting agents that require
fewer clinic visits.
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